Clinical predictors of Bevacizumab-associated intestinal perforation in patients with non-small cell lung cancer: A retrospective study

Trial Profile

Clinical predictors of Bevacizumab-associated intestinal perforation in patients with non-small cell lung cancer: A retrospective study

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Mar 2018 New trial record
    • 14 Mar 2018 Results published in the Investigational New Drugs
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top